EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

NLC-Based Rifampicin Delivery System: Development and Characterization for Improved Drug Performance Against Staphylococcus aureus

Javiera Carrasco-Rojas iD, Felipe I Sandoval iD, Christina M A P Schuh iD, Carlos F Lagos iD, Javier O Morales iD, Francisco Arriagada iD, Andrea C Ortiz iD

Pharmaceutics · 19.06.2025 · 17 (6) · 799

DOI: 10.3390/pharmaceutics17060799 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmaceutics, online erschienen am 19.06.2025. Verfasst von Javiera Carrasco-Rojas und 6 weiteren Autor:innen. Beteiligte Einrichtung: Departamento de Ciencias y Tecnología Farmacéutica, Facultad de Ciencias Químicas y Farmacéuticas, Universidad de Chile, Santiago 8380494, Chile. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fondo Nacional de Desarrollo Científico y Tecnológico, FONDEF, Agencia Nacional de Investigación y Desarrollo.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: Rifampicin is a typical antibiotic used for the treatment of Staphylococcus aureus (S. aureus) infections; however, its clinical utility is limited by poor aqueous solubility, chemical instability, and increasing bacterial resistance. Nanostructured lipid carriers (NLCs) offer a promising strategy to improve drug solubility, stability, and antimicrobial performance.

Methods

In this study, rifampicin-loaded NLC (NLC-RIF) was developed using a hot homogenization with a low energy method and characterized in terms of particle size, polydispersity index, zeta potential, encapsulation efficiency, colloidal stability, and drug loading.

Results

In vitro release studies under sink conditions demonstrated a biphasic release pattern, best described by the Korsmeyer–Peppas model, suggesting a combination of diffusion and matrix erosion mechanisms. Antimicrobial activity against S. aureus revealed a substantial increase in potency for NLC-RIF, with an IC50 of 0.46 ng/mL, approximately threefold lower than that of free rifampicin. Cytotoxicity assays in HepG2 cells confirmed over 90% cell viability across all tested concentrations.

Conclusions

These findings highlight the potential of NLC-RIF as a biocompatible and effective nanocarrier system for enhancing rifampicin delivery and antibacterial activity.

Schlagwörter

Stichwörter der Autor:innen

HepG2 cellStaphylococcus aureusantibioticdrug releasenanostructured lipid carrierrifampicin

Autor:innen und Institutionen

  • Departamento de Ciencias y Tecnología Farmacéutica, Facultad de Ciencias Químicas y Farmacéuticas, Universidad de Chile, Santiago 8380494, Chile.
  • Centro de Medicina Regenerativa, Facultad de Medicina, Clínica Alemana-Universidad del Desarrollo, Santiago 7550000, Chile.
  • Escuela de Química y Farmacia, Facultad de Ciencias, Universidad San Sebastián, Campus Los Leones, Lota 2465, Providencia, Santiago 7510157, Chile.
  • Centro Basal Ciencia & Vida, Fundación Ciencia & Vida, Av. del Valle Norte 725, Huechuraba 8580702, Chile.
  • Centro de Nuevos Fármacos para Hipertensión e Insuficiencia Cardíaca, CENDHY, Santiago 8380494, Chile.
  • Centro Avanzado de Enfermedades Crónicas, ACCDiS, Santiago 8380494, Chile.

ORCID-Profile: Javiera Carrasco-Rojas, Felipe I Sandoval, Christina M A P Schuh, Carlos F Lagos, Javier O Morales, Francisco Arriagada, Andrea C Ortiz

Förderung

  • Fondo Nacional de Desarrollo Científico y Tecnológico
  • FONDEF
  • Agencia Nacional de Investigación y Desarrollo
  • FONDAP
  • FONDEQUIP
  • FONDECYT Project
  • Regular FONDECYT Project
  • FONDEF Project

Zitieren

APA

Carrasco-Rojas, J., Sandoval, F. I., Schuh, C. M. A. P., Lagos, C. F., Morales, J. O., Arriagada, F., & Ortiz, A. C. (2025). NLC-Based Rifampicin Delivery System: Development and Characterization for Improved Drug Performance Against Staphylococcus aureus. Pharmaceutics, 17(6), 799. https://doi.org/10.3390/pharmaceutics17060799

Vancouver

Carrasco-Rojas J, Sandoval FI, Schuh CMAP, Lagos CF, Morales JO, Arriagada F, et al. NLC-Based Rifampicin Delivery System: Development and Characterization for Improved Drug Performance Against Staphylococcus aureus. Pharmaceutics. 2025;17(6):799. doi:10.3390/pharmaceutics17060799

BibTeX
@article{CarrascoRojas2025,
  author = {Carrasco-Rojas, Javiera and Sandoval, Felipe I and Schuh, Christina M A P and Lagos, Carlos F and Morales, Javier O and Arriagada, Francisco and Ortiz, Andrea C},
  title = {NLC-Based Rifampicin Delivery System: Development and Characterization for Improved Drug Performance Against Staphylococcus aureus},
  journal = {Pharmaceutics},
  year = {2025},
  volume = {17},
  number = {6},
  pages = {799},
  doi = {10.3390/pharmaceutics17060799}
}
Kostenlos starten →